Respect ‐meso: an international multicentre non‐blinded randomized controlled trial to assess the impact of regular early specialist palliative care in malignant pleural mesothelioma

Source: Respirology - Category: Respiratory Medicine Tags: Late Breaking Oral Abstracts Source Type: research

Related Links:

Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at “But we’ve shown a meaningful survival.” Kluger,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer, with a five-year survival rate of
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and mediastinal malignancies Source Type: research
ConclusionsEpirubicin has a modest clinical activity in pre-treated elderly patients with MPM in progression after one or two regimens, with an acceptable toxicity profile. It could be considered as a palliative treatment.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: ITP is safe, tolerable, and useful but its inclusion in the multidisciplinary palliative treatment of progressive MPM patients should be investigated in a larger multicentre controlled study. PMID: 31424688 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
The Baylor College of Medicine in Houston has opened its latest clinical trial for mesothelioma patients to study the effectiveness of a novel immunotherapy combination. The nonsurgical, single-center study is looking for a dozen patients whose pleural mesothelioma has progressed after at least one regimen of chemotherapy. The phase II clinical trial involves Opdivo (nivolumab) and MTG201, a modified adenovirus designed to increase the efficacy of certain types of immunotherapy drugs. The combination was especially effective in preclinical mouse models. “We’re excited about the prospects of this combination,&rd...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsComplete CRS and HIPEC can be achieved in strictly selected patient with unresectable PM at diagnosis after repeated PIPAC session with palliative intent.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
This study has terrific significance and could be extremely important,” Harbut, clinical professor of internal medicine at Wayne State University and Michigan State University, told The Mesothelioma Center at “We’re going after this one with great guns.” The study is part of a new partnership between Owlstone Medical — the Breath Biopsy inventor in the United Kingdom — and the International Association of Heat and Frost Insulators and Allied Workers, a building trade union that covers the United States and Canada. Early Diagnosis Still a Rarity The first part of the study ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer & Oncology | Mesothelioma | Palliative | Palliative Care